STOCK TITAN
  1. Home
  2. News
  3. REGN

Regeneron Pharmaceuticals, Inc. - REGN STOCK NEWS

IMPACT
SENTIMENT
REGN : Nasdaq
Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
IMPACT
SENTIMENT
REGN : Nasdaq
EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review
IMPACT
SENTIMENT
REGN : Nasdaq SNY : Nasdaq
Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old
clinical trial
IMPACT
SENTIMENT
REGN : Nasdaq
Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022
conferences
IMPACT
SENTIMENT
REGN : Nasdaq
Regeneron Elects Dr. Craig B. Thompson to Board of Directors
management
IMPACT
SENTIMENT
REGN : Nasdaq
Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
IMPACT
SENTIMENT
REGN : Nasdaq SNY : Nasdaq
Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
IMPACT
SENTIMENT
REGN : Nasdaq NTLA : Nasdaq
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
clinical trial
IMPACT
SENTIMENT
REGN : Nasdaq SNY : Nasdaq
Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet
clinical trial
IMPACT
SENTIMENT
REGN : Nasdaq ALNY : Nasdaq
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
clinical trial
Stock REGN logo
Regeneron Pharmaceuticals, Inc.

Nasdaq:REGN

REGN Rankings

#141 Ranked by Market Cap
#1795 Ranked by Stock Gains
N/A Ranked by Dividends

REGN Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Tarrytown

About REGN

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.